SPT6 Lentiviral Activation Particles (h): sc-406219-LAC

Human SUPT6H encodes SPT6, a conserved transcription elongation factor that binds RNA polymerase II and coordinates nucleosome reassembly during active transcription. SPT6 functions as a histone chaperone and couples elongation with chromatin remodeling, contributing to regulation of promoter-proximal pausing, co-transcriptional RNA processing, and maintenance of genome stability. Through its roles in chromatin organization and transcriptional fidelity, altered SPT6 activity can perturb gene expression programs linked to cell identity, proliferation, and stress responses, making SUPT6H a relevant node for studying transcriptional dysregulation in disease-associated pathways.

SPT6 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient SUPT6H upregulation across a broader range of human cell types.

SPT6 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the SUPT6H transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous SPT6 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native SUPT6H genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.